Shanxi C&Y Pharmaceutical Group300254.SZValuation Analysis

As of Oct 19, 2026, Shanxi C&Y Pharmaceutical Group (300254.SZ) trades at a P/E of 77.00x, P/B of 4.94x, P/S of 3.15x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 34th percentile over the trailing 10Y window (vs. 48th percentile over 3Y); P/B sits at the 79th percentile over the trailing 10Y window (vs. 42nd percentile over 3Y); P/S sits at the 75th percentile over the trailing 10Y window (vs. 50th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 75th percentile within its industry and the 74th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 45.4 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shanxi C&Y Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.